Search by Drug Name or NDC

    NDC 00173-0681-22 RELENZA 5 mg/1 Details

    RELENZA 5 mg/1

    RELENZA is a RESPIRATORY (INHALATION) POWDER in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by GlaxoSmithKline LLC. The primary component is ZANAMIVIR.

    Product Information

    NDC 00173-0681
    Product ID 0173-0681_276882d0-98d8-4f65-a341-62953e316217
    Associated GPIs 12504080008020
    GCN Sequence Number 043119
    GCN Sequence Number Description zanamivir BLST W/DEV 5 MG INHALATION
    HIC3 W5A
    HIC3 Description ANTIVIRALS, GENERAL
    GCN 92221
    HICL Sequence Number 020398
    HICL Sequence Number Description ZANAMIVIR
    Brand/Generic Brand
    Proprietary Name RELENZA
    Proprietary Name Suffix n/a
    Non-Proprietary Name zanamivir
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form POWDER
    Route RESPIRATORY (INHALATION)
    Active Ingredient Strength 5
    Active Ingredient Units mg/1
    Substance Name ZANAMIVIR
    Labeler Name GlaxoSmithKline LLC
    Pharmaceutical Class Neuraminidase Inhibitor [EPC], Neuraminidase Inhibitors [MoA]
    DEA Schedule n/a
    Marketing Category NDA
    Application Number NDA021036
    Listing Certified Through 2024-12-31

    Package

    NDC 00173-0681-22 (00173068122)

    NDC Package Code 0173-0681-22
    Billing NDC 00173068122
    Package 5 PACKAGE in 1 CARTON (0173-0681-22) / 4 POWDER in 1 PACKAGE
    Marketing Start Date 2007-03-09
    NDC Exclude Flag N
    Pricing Information N/A